No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study

Basit Öğe Kaydı
dc.authoridDagdelen, Selcuk/0000-0002-0513-1750
dc.authoridDemirci, Ibrahim/0000-0003-0498-3115
dc.authoridSonmez, Alper/0000-0002-9309-7715
dc.authoridsahin, mustafa/0000-0002-4718-0083
dc.authoridSatman, Ilhan/0000-0001-8613-1797
dc.authoridTASCI, ILKER/0000-0002-0936-2476
dc.authorwosidsalman, serpil/GRX-8413-2022
dc.authorwosidDagdelen, Selcuk/A-9432-2017
dc.authorwosidDemirci, Ibrahim/AAR-3277-2020
dc.authorwosidSonmez, Alper/H-8588-2019
dc.authorwosidUstun, Yaprak/KFQ-9767-2024
dc.authorwosidsahin, mustafa/AAH-3394-2019
dc.authorwosidŞahin, İbrahim/HHY-8303-2022
dc.contributor.authorAtmaca, A.
dc.contributor.authorDemirci, I.
dc.contributor.authorHaymana, C.
dc.contributor.authorTasci, I.
dc.contributor.authorSahin, I.
dc.contributor.authorCakal, E.
dc.contributor.authorAta, N.
dc.date.accessioned2024-08-04T20:50:33Z
dc.date.available2024-08-04T20:50:33Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThis study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, and mortality was not altered in individuals taking anti-osteoporosis drugs, suggesting no safety issues during a COVID-19 infection. Introduction Whether patients with COVID-19 receiving anti-osteoporosis drugs have lower risk of worse outcomes has not been reported yet. The aim of this study was to evaluate the association of anti-osteoporosis drug use with COVID-19 outcomes in women. Methods Data obtained from a nationwide, multicenter, retrospective cohort of patients diagnosed with COVID-19 from March 11th to May 30th, 2020 was retrieved from the Turkish Ministry of Health Database. Women 50 years or older with confirmed COVID-19 who were receiving anti-osteoporosis drugs were compared with a 1:1 propensity score-matched COVID-19 positive women who were not receiving these drugs. The primary outcomes were hospitalization, ICU (intensive care unit) admission, and mortality. Results A total of 1997 women on anti-osteoporosis drugs and 1997 control patients were analyzed. In the treatment group, 1787 (89.5%) women were receiving bisphosphonates, 197 (9.9%) denosumab, and 17 (0.9%) teriparatide for the last 12 months. Hospitalization and mortality rates were similar between the treatment and control groups. ICU admission rate was lower in the treatment group (23.0% vs 27.0%, p = 0.013). However, multivariate analysis showed that anti-osteoporosis drug use was not an independent associate of any outcome. Hospitalization, ICU admission, and mortality rates were similar among bisphosphonate, denosumab, or teriparatide users. Conclusion Results of this nationwide study showed that preexisting use of anti-osteoporosis drugs in women did not alter the COVID-19-related risk of hospitalization, ICU admission, and mortality. These results do not suggest discontinuation of these drugs during a COVID-19 infection.en_US
dc.identifier.doi10.1007/s00198-021-06067-2
dc.identifier.endpage282en_US
dc.identifier.issn0937-941X
dc.identifier.issn1433-2965
dc.identifier.issue1en_US
dc.identifier.pmid34402949en_US
dc.identifier.scopus2-s2.0-85112771150en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage273en_US
dc.identifier.urihttps://doi.org/10.1007/s00198-021-06067-2
dc.identifier.urihttps://hdl.handle.net/11616/100140
dc.identifier.volume33en_US
dc.identifier.wosWOS:000685594500001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofOsteoporosis Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBisphosphonatesen_US
dc.subjectCOVID-19en_US
dc.subjectDenosumaben_US
dc.subjectMortalityen_US
dc.subjectOsteoporosisen_US
dc.subjectTeriparatideen_US
dc.titleNo association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu